Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,946
Views
7
CrossRef citations to date
0
Altmetric
Report

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

Baoshan Zhanga Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Jason Gormana Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Young D. Kwona Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Amarendra Pegua Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Cara W. Chaoa Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Tracy Liua Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Mangaiarkarasi Asokana Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Michael F. Bendera Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Tatsiana Bylunda Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Leland Damrona Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Deepika Gollapudia Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Paula Leia Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Yile Lia Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Cuiping Liua Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Mark K. Loudera Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Krisha McKeea Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Adam S. Oliaa Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Reda Rawia Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Arne Schönb Department of Biology, Johns Hopkins University, Baltimore, MD, USAView further author information
,
Shuishu Wanga Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Eun Sung Yanga Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Yongping Yanga Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Kevin Carltona Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Nicole A. Doria-Rosea Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
,
Lawrence Shapiroc Department of Biochemistry, Columbia University, New York, NY, USAView further author information
,
Michael S. Seamand Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USAView further author information
,
John R. Mascolaa Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USAView further author information
&
Peter D. Kwonga Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USA;c Department of Biochemistry, Columbia University, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3560-232XView further author information
ORCID Icon show all
Article: 2165390 | Received 21 Sep 2022, Accepted 30 Dec 2022, Published online: 02 Feb 2023

References

  • Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, deCamp AC, Rudnicki E, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003–12. PMID: 33730454. doi:10.1056/NEJMoa2031738.
  • Chuang GY, Zhou J, Acharya P, Rawi R, Shen CH, Sheng Z, Zhang B, Zhou T, Bailer RT, Dandey VP, et al. Structural survey of broadly neutralizing antibodies targeting the HIV-1 env trimer delineates epitope categories and characteristics of recognition. Structure. 2019;27(1):196–206 e6. PMID: 30471922. doi:10.1016/j.str.2018.10.007.
  • Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–89. PMID: 19729618. doi:10.1126/science.1178746.
  • Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–70. PMID: 21849977. doi:10.1038/nature10373.
  • Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A. 2014;111:17624–29. PMID: 25422458. doi:10.1073/pnas.1415789111.
  • Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol. 2016;90:76–91. PMID: 26468542. doi:10.1128/JVI.01791-15.
  • Gorman J, Chuang GY, Lai YT, Shen CH, Boyington JC, Druz A, Geng H, Louder MK, McKee K, Rawi R, et al. Structure of super-potent antibody CAP256-VRC26.25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition. Cell Rep. 2020;31:107488. PMID: 32268107. doi:10.1016/j.celrep.2020.03.052.
  • Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity. 2017;46:690–702. PMID: 28423342. doi:10.1016/j.immuni.2017.03.017.
  • McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480:336–43. PMID: 22113616. doi:10.1038/nature10696.
  • Lee M, Changela A, Gorman J, Rawi R, Bylund T, Chao CW, Lin BC, Louder MK, Olia AS, Zhang B, et al. Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces. Nat Commun. 2021;12(1):6470. PMID: 34753907. doi:10.1038/s41467-021-26579-z.
  • Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–12. PMID: 23151583. doi:10.1038/nature11544.
  • Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. PMID: 20616233. doi:10.1126/science.1187659.
  • Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333(6049):1593–602. PMID: 21835983. doi:10.1126/science.1207532.
  • McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med. 2012;209(6):1091–103. PMID: 22641382. doi:10.1084/jem.20112655.
  • Zhou T, Chen L, Gorman J, Wang S, Kwon YD, Lin BC, Louder MK, Rawi R, Stancofski ED, Yang Y, et al. Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. Structure. 2022;30(6):862–75 e4. PMID: 35413243. doi:10.1016/j.str.2022.03.012.
  • Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, Gengiah T, Archary D, Samsunder N, Rose ND, et al. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open. 2020;10(11):e042247. PMID: 33243815. doi:10.1136/bmjopen-2020-042247.
  • Cai CX, Doria-Rose NA, Schneck NA, Ivleva VB, Tippett B, Shadrick WR, O’Connell S, Cooper JW, Schneiderman Z, Zhang B, et al. Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. Sci Rep. 2022;12(1):8433. PMID: 35589938. doi:10.1038/s41598-022-12423-x.
  • Zhang B, Gollapudi D, Gorman J, O’Dell S, Damron LF, McKee K, Asokan M, Yang ES, Pegu A, Lin BC, et al. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. Sci Rep. 2022;12(1):17876. PMID: 36284200. doi:10.1038/s41598-022-22435-2.
  • Rawi R, Rutten L, Lai YT, Olia AS, Blokland S, Juraszek J, Shen CH, Tsybovsky Y, Verardi R, Yang Y, et al. Automated design by structure-based stabilization and consensus repair to achieve prefusion-closed envelope trimers in a wide variety of HIV strains. Cell Rep. 2020;33(8):108432. PMID: 33238130. doi:10.1016/j.celrep.2020.108432.
  • Gulla K, Cibelli N, Cooper JW, Fuller HC, Schneiderman Z, Witter S, Zhang Y, Changela A, Geng H, Hatcher C, et al. A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. Vaccine. 2021;39(25):3379–87. PMID: 34020817. doi:10.1016/j.vaccine.2021.04.063.
  • Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015;22(7):522–31. PMID: 26098315. doi:10.1038/nsmb.3051.
  • Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d. PMID: 21053952
  • Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385–92. PMID: 20159773. doi:10.1093/protein/gzq009.
  • Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112(19):5997–6002. doi:10.1073/pnas.1408766112. PMID: 25918417
  • Yin Y, Quinlan BD, Ou T, Guo Y, He W, Farzan M. In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25. Proc Natl Acad Sci U S A. 2021;118(29):e2106203118. doi:10.1073/pnas.2106203118. PMID: 34261793
  • Davis-Gardner ME, Alfant B, Weber JA, Gardner MR, Farzan M. A bispecific antibody that simultaneously recognizes the V2- and V3-glycan epitopes of the HIV-1 envelope glycoprotein is broader and more potent than its parental antibodies. mBio. 2020;11:e03080–19. PMID: 31937648. doi:10.1128/mBio.03080-19.
  • Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017;9(406):eaal1321. PMID: 28878010. doi:10.1126/scitranslmed.aal1321.
  • Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017;358(6359):85–90. PMID: 28931639. doi:10.1126/science.aan8630.
  • Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514(7523):455–61. PMID: 25296255. doi:10.1038/nature13808.
  • Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618. PMID: 24068931. doi:10.1371/journal.ppat.1003618.
  • Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. PMID: 24291345. doi:10.1016/j.jim.2013.11.022.
  • Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016;352(6287):828–33. PMID: 27174988. doi:10.1126/science.aae0474.
  • Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016;12(3):e1005520. PMID: 27028935. doi:10.1371/journal.ppat.1005520.
  • Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. PMID: 25142607. doi:10.1128/JVI.02213-14.
  • Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013;340:751–56. PMID: 23661761. doi:10.1126/science.1233989.
  • Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, Stagg S, Potter CS, Carragher B. Automated molecular microscopy: the new Leginon system. J Struct Biol. 2005;151:41–60. PMID: 15890530. doi:10.1016/j.jsb.2005.03.010.
  • Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290–96. PMID: 28165473. doi:10.1038/nmeth.4169.
  • Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Pai RK, Read RJ, Romo TD, et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat. 2004;11:53–55. S0909049503024130 [pii]. PMID: 14646133. doi:10.1107/S0909049503024130.
  • Terwilliger TC, Ludtke SJ, Read RJ, Adams PD, Afonine PV. Improvement of cryo-EM maps by density modification. Nat Methods. 2020;17:923–27. PMID: 32807957. doi:10.1038/s41592-020-0914-9.
  • Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32. PMID: 15572765. doi:10.1107/S0907444904019158.
  • Davis IW, Murray LW, Richardson JS, Richardson DC. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 2004;32:W615–9. PMID: 15215462. doi:10.1093/nar/gkh398.
  • Barad BA, Echols N, Wang RY, Cheng Y, DiMaio F, Adams PD, Fraser JS. EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. Nat Methods. 2015;12:943–46. PMID: 26280328. doi:10.1038/nmeth.3541.
  • Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70–82. PMID: 32881101. doi:10.1002/pro.3943.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.